Eisai's Halaven® (Eribulin Mesylate) Arrives at Chinese Ports on November 25, Bringing New Hope to Patients with Advanced Breast Cancer

Shanghai, November 26, 2019 /PRNewswire/ -- On November 25, 2019, Halaven®, a next-generation chemotherapy drug developed by Eisai Co., Ltd. of Japan for the treatment of advanced breast cancer^®(Eribulin Mesylate) has arrived at Chinese ports and is about to enter the Chinese market.

Breast cancer is the most prevalent malignant tumor among women in China. In stark contrast, however, very few chemotherapy drugs for the treatment of advanced breast cancer have been launched in China over the past decade. Many patients with advanced breast cancer struggle on their journey for survival, experiencing cycles of recurrence, medication changes, further recurrence, and subsequent medication switches, until they reach a point where no therapeutic options remain. Physicians, patients, and their families are urgently seeking and anticipating the approval of new chemotherapy agents. Halaven^®The arrival of [treatment/drug] has brought new hope to patients with advanced breast cancer in China.

Halaven^®A gift from the ocean, extracted from Halichondria okadai in Aburatsubo, Kanagawa Prefecture, Japan. Hai Le Wei^®After more than 20 years of research and development and a complex 62-step synthesis process, it was hailed by Nature magazine as the Mount Everest of drug synthesis.¹, and was ultimately launched in the United States in 2010. After nearly 10 years of clinical validation, Lenvima^®It has been launched in nearly 70 countries, benefiting tens of thousands of patients with advanced breast cancer worldwide.

Halaven^®Possesses a unique anti-tumor mechanism, compared to other treatment regimens, isThe Only OneChemotherapeutic agents that can prolong survival in patients with advanced breast cancer as monotherapy. Due to Halaven^®Significant Efficacy², numerous domestic and international guidelines, including the NCCN Guidelines in the United States, the ABC Guidelines in Europe, and the Chinese Anti-Cancer Association’s Guidelines and Specifications for the Diagnosis and Treatment of Breast Cancer, consistently recommend Halaven.^®Preferred Chemotherapeutic Agents for Patients with Advanced Breast Cancer^3,4,5,6。

Haleon^®While prolonging patient survival, it can also significantly improve patients' quality of life. Nausea, vomiting, hair loss, hand-foot syndrome, and peripheral neuritis are common adverse reactions to chemotherapy. These adverse reactions can greatly affect patients' normal lives, thereby reducing their willingness to continue treatment and ultimately impacting treatment outcomes. Halaven^®Significantly reduces the incidence of severe adverse reactions perceived by such patients², significantly improving patients' treatment experience and quality of life, minimizing the physical and psychological impact of chemotherapy, thereby strengthening patients' confidence to continue treatment.

With Halaven^®the arrival, Eisai China Pharmaceutical will continue to practicehhc(Human Health Care) The corporate philosophy of “Caring for Human Health” benefits more Chinese patients with advanced breast cancer.

[References]

1.  Nature 2010. 11

2. Drug Package Insert

3. NCCN Guidelines 2019 V2.0

4. ABC4 Guidelines

5. Guidelines and Standards for the Diagnosis and Treatment of Breast Cancer by the China Anti-Cancer Association (2019 Edition), Chinese Journal of Cancer. 2019, 29(8).

6. Chinese Expert Consensus on the Clinical Diagnosis and Treatment of Advanced Breast Cancer (2018 Edition), Chinese Journal of Oncology, 2019, 40(9).